How has Dianthus Therapeutics's other commercial liabilities changed year-over-year?

Dianthus Therapeutics's other commercial liabilities increased by 290.1% year-over-year, from $7.98M to $31.13M.

What is the long-term trend for Dianthus Therapeutics's other commercial liabilities?

Over 3 years (2022 to 2025), Dianthus Therapeutics's other commercial liabilities has grown at a 43.3% compound annual growth rate (CAGR), from $6.61M to $19.45M.

Dianthus Therapeutics DNTH Other Commercial Liabilities

Other Commercial Liabilities at other companies

Johnson & JohnsonJNJ

——

AmgenAMGN

——

Kymera TherapeuticsKYMR

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's other commercial liabilities?: Dianthus Therapeutics (DNTH) reported other commercial liabilities of $31.13M in Q1 2026.
How has Dianthus Therapeutics's other commercial liabilities changed year-over-year?: Dianthus Therapeutics's other commercial liabilities increased by 290.1% year-over-year, from $7.98M to $31.13M.
What is the long-term trend for Dianthus Therapeutics's other commercial liabilities?: Over 3 years (2022 to 2025), Dianthus Therapeutics's other commercial liabilities has grown at a 43.3% compound annual growth rate (CAGR), from $6.61M to $19.45M.